Bithionol inhibits ovarian cancer cell growth In Vitro - studies on mechanism(s) of action

[1]  K. O'Byrne,et al.  Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy , 2013, Front. Oncol..

[2]  Stanley He,et al.  MYCN and the epigenome , 2013, Front. Oncol..

[3]  Azadeh Meshkini,et al.  Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. , 2012, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[4]  E. Bourdon,et al.  Autotaxin protects microglial cells against oxidative stress. , 2012, Free radical biology & medicine.

[5]  A. Simon,et al.  Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia , 2011, Cell cycle.

[6]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[7]  D. Braddock.  Autotaxin and lipid signaling pathways as anticancer targets. , 2010, Current opinion in investigational drugs.

[8]  R. Agarwal,et al.  Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. , 2010, Cellular signalling.

[9]  Ruili Huang,et al.  Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. , 2010, Biochemical pharmacology.

[10]  D. Braddock,et al.  Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion , 2008, Molecular Cancer Therapeutics.

[11]  Y. Yoshida,et al.  DNA-binding activity of NF-kappaB and phosphorylation of p65 are induced by N-acetylcysteine through phosphatidylinositol (PI) 3-kinase. , 2008, Molecular immunology.

[12]  S. Kaye,et al.  The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin , 2007, Clinical Cancer Research.

[13]  Yan Xu,et al.  Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion , 2007, Oncogene.

[14]  R. Carón,et al.  Mifepristone Inhibits Ovarian Cancer Cell Growth In vitro and In vivo , 2007, Clinical Cancer Research.

[15]  R. Gust,et al.  Non Platinum Metal Complexes as Anti‐cancer Drugs , 2007, Archiv der Pharmazie.

[16]  T. Herzog.  The current treatment of recurrent ovarian cancer , 2006, Current oncology reports.

[17]  D. Green,et al.  Staining of suspension cells with hoechst 33258 to detect apoptosis. , 2006, CSH protocols.

[18]  Dong-Hyun Kim,et al.  Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. , 2005, Gynecologic oncology.

[19]  K. Conklin.  Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness , 2004, Integrative cancer therapies.

[20]  W. Gregory,et al.  Long‐term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age‐matched normal population , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[21]  A. Parrill,et al.  Molecular mechanisms of lysophosphatidic acid action. , 2003, Progress in lipid research.

[22]  E. Venkatraman,et al.  Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. , 2003, Gynecologic oncology.

[23]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[24]  P. Elson,et al.  Unfolding the pathophysiological role of bioactive lysophospholipids. , 2003, Current drug targets. Immune, endocrine and metabolic disorders.

[25]  J. Chun,et al.  Lysophosphatidic acid as a novel cell survival/apoptotic factor. , 2002, Biochimica et biophysica acta.

[26]  Yusuke Nakamura,et al.  Involvement of FKHR-Dependent TRADD Expression in Chemotherapeutic Drug-Induced Apoptosis , 2002, Molecular and Cellular Biology.

[27]  B. Aggarwal,et al.  Chemopreventive Agents Induce Suppression of Nuclear Factor‐κB Leading to Chemosensitization , 2002, Annals of the New York Academy of Sciences.

[28]  W. V. Berghe,et al.  Regulation of the transcriptional activity of the nuclear factor-κB p65 subunit , 2002 .

[29]  E. Shacter,et al.  Distinct Modes of Cell Death Induced by Different Reactive Oxygen Species , 2002, The Journal of Biological Chemistry.

[30]  Michael Fraser,et al.  Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[31]  Y. S. Kim,et al.  Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. , 2001, Cancer research.

[32]  Y. Kikuchi.  [The mechanism of cisplatin-resistance in ovarian cancer]. , 2001, Human cell.

[33]  G. Mills,et al.  XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. , 2001, Cancer research.

[34]  G. Gores,et al.  Apoptosis in cancer: cause and cure , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[35]  K. Irani.  Oxidant signaling in vascular cell growth, death, and survival : a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. , 2000, Circulation research.

[36]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[37]  W. El-Deiry,et al.  Cell cycle control as a basis for cancer drug development (Review). , 2000, International journal of oncology.

[38]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[39]  J. Buolamwini.  Cell cycle molecular targets in novel anticancer drug discovery. , 2000, Current pharmaceutical design.

[40]  Suk Woo Nam,et al.  Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells , 2000, Oncogene.

[41]  J. Cusack,et al.  NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[42]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[43]  R. Kinscherf,et al.  Modulating apoptosis: current applications and prospects for future drug development. , 1999, Current medicinal chemistry.

[44]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[45]  R. Weinberg,et al.  Cell-cycle control and its watchman , 1996, Nature.

[46]  J. Warwick,et al.  The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. , 1996, Cancer research.

[47]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[48]  J C Reed,et al.  The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. , 1995, Oncogene.

[49]  G. Mills,et al.  Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  G. Kroemer,et al.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death , 1995, The Journal of experimental medicine.

[51]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[52]  S. Elledge,et al.  Inhibition of cyclin-dependent kinases by p21. , 1995, Molecular biology of the cell.

[53]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[54]  Y. Bacq,et al.  Successful treatment of acute fascioliasis with bithionol , 1991, Hepatology.

[55]  W. Leonard,et al.  Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[56]  H. G. Khorana,et al.  Studies on polynucleotides , 1965 .

[57]  W. E. Razzell,et al.  Studies on polynucleotides. III. Enzymic degradation; substrate specificity and properties of snake venom phosphodiesterase. , 1959, The Journal of biological chemistry.

[58]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[59]  S. Linder,et al.  Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA , 2007, International journal of cancer.

[60]  G. Haegeman,et al.  Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. , 2002, Biochemical pharmacology.

[61]  Jiayuh Lin,et al.  Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. , 2000, Anticancer research.

[62]  H. Arts,et al.  Options for modulation of drug resistance in ovarian cancer. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[63]  M. Sano,et al.  Chemotherapy of Paragonimiasis with Bithionol. II. Clinical Observations on the Treatment with Bithionol. , 1961 .